心脏的安全性和有效性 6 左心室辅助系统
Zhibing Qiu1, Xiaochun Song, Hongwei Shi
1From the Department of Cardiothoracic and Vascular Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
概括
康哈特6左心室辅助系统 (LVAS) 在末期心力衰竭患者中显示出有前途的中期生存和心脏功能改善. 它的安全概况是可以管理的,没有报告设备故障.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 机械循环支持 机械循环支持
背景情况:
- 最终阶段心力衰竭需要先进的治疗选择.
- 左心室辅助系统 (LVAS) 为等待移植或作为目的地治疗的患者提供了关键的解决方案.
研究的目的:
- 为了评估Corheart 6 LVAS的疗效和安全性.
- 为了评估临床结果,包括存活率和心脏功能,在接受Corheart 6 LVAS的终期心力衰竭患者中.
主要方法:
- 南京第一医院的回顾性队列研究 (2022年3月 - 2024年3月).
- 招募了28名心脏衰竭末期患者,他们植入了Corheart 6 LVAS.
- 主要终点:没有致残性中风的6个月生存期.
主要成果:
- 3个月100%的生存率,89.3%在6个月 (3人死亡).
- 植入后观察到心脏功能的显著改善.
- 没有血栓,血液溶解或设备故障;稳定的血液溶解标记.
结论:
- 心脏6 LVAS显示了有利的中期存活率和心脏功能改善.
- 该设备为严重心力衰竭患者提供了可管理的安全概况.
- 需要进一步研究治疗感染和心律失常等不良事件的方法.
相关概念视频
Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Heart Failure II: Pathophysiology
734
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
734
Cardiomyopathy V: Interprofessional Care
339
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
Heart Failure I: Introduction
710
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
710
Cardiac Catheterization III: Left Heart Catheterization
597
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
597


